Entrada Therapeutics (TRDA) Insider Trading & Ownership $7.07 -0.50 (-6.58%) As of 11:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Entrada Therapeutics (NASDAQ:TRDA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.11%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$2.44M Get TRDA Insider Trade Alerts Want to know when executives and insiders are buying or selling Entrada Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TRDA Insider Buying and Selling by Quarter Entrada Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/30/2025Kush ParmarDirectorSell25,000$6.81$170,250.00 6/30/2025Ventures V L.P. 5AmMajor ShareholderSell18,578$6.81$126,516.18 6/30/2025Ventures V L.P. 5AmMajor ShareholderSell6,422$6.81$43,733.82 6/27/2025Kush ParmarDirectorSell75,000$6.91$518,250.00 6/27/2025Ventures V L.P. 5AmMajor ShareholderSell55,735$6.91$385,128.85 6/27/2025Ventures V L.P. 5AmMajor ShareholderSell19,265$6.91$133,121.15 12/10/2024Bioventures 2018 L.P. MpmMajor ShareholderSell22,935$20.77$476,359.95 12/2/2024Kory James WentworthCFOSell5,000$20.00$100,000.00 11/29/2024Kory James WentworthCFOSell1,000$19.97$19,970.00 11/13/2024Natarajan SethuramanInsiderSell2,700$20.04$54,108.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 11/11/2024Kory James WentworthCFOSell8,637$19.98$172,567.26 11/11/2024Natarajan SethuramanInsiderSell1,409$20.01$28,194.09 10/16/2024Natarajan SethuramanInsiderSell600$18.00$10,800.00 9/26/2024Nathan J DowdenCOOSell847$16.00$13,552.00 9/9/2024Kory James WentworthCFOSell3,195$14.97$47,829.15 9/9/2024Natarajan SethuramanInsiderSell2,642$15.09$39,867.78 9/9/2024Nathan J DowdenCOOSell1,904$15.07$28,693.28 9/6/2024Natarajan SethuramanInsiderSell600$15.24$9,144.00 9/6/2024Nathan J DowdenCOOSell399$15.19$6,060.81 7/15/2024Dipal DoshiCEOSell1,600$17.81$28,496.00 7/15/2024Natarajan SethuramanInsiderSell638$18.00$11,484.00 7/12/2024Dipal DoshiCEOSell300$18.00$5,400.00 7/12/2024Natarajan SethuramanInsiderSell600$18.00$10,800.00 (Data available from 1/1/2013 forward) TRDA Insider Trading Activity - Frequently Asked Questions Who is on Entrada Therapeutics' Insider Roster? The list of insiders at Entrada Therapeutics includes Bioventures 2018 L.P. Mpm, Dipal Doshi, Kory James Wentworth, Kush Parmar, Natarajan Sethuraman, Nathan J Dowden, Nerissa Kreher, Peter S Kim, and Ventures V L.P. 5Am. Learn more on insiders at TRDA. What percentage of Entrada Therapeutics stock is owned by insiders? 8.11% of Entrada Therapeutics stock is owned by insiders. Learn more on TRDA's insider holdings. Which Entrada Therapeutics insiders have been buying company stock? The following insider purchased TRDA shares in the last 24 months: Peter S Kim ($151,226.80). How much insider buying is happening at Entrada Therapeutics? Insiders have purchased a total of 11,172 TRDA shares in the last 24 months for a total of $151,226.80 bought. Which Entrada Therapeutics insiders have been selling company stock? The following insiders have sold TRDA shares in the last 24 months: Bioventures 2018 L.P. Mpm ($476,359.95), Dipal Doshi ($184,956.00), Kory James Wentworth ($611,065.63), Kush Parmar ($688,500.00), Natarajan Sethuraman ($380,829.12), Nathan J Dowden ($118,998.93), Nerissa Kreher ($266,748.00), and Ventures V L.P. 5Am ($688,500.00). How much insider selling is happening at Entrada Therapeutics? Insiders have sold a total of 317,709 Entrada Therapeutics shares in the last 24 months for a total of $3,415,957.63 sold. Entrada Therapeutics Key ExecutivesMr. Dipal Doshi (Age 48)CEO & Director Compensation: $968.21kMr. Nathan J. Dowden (Age 53)President & COO Compensation: $694.3kDr. Natarajan Sethuraman Ph.D. (Age 62)Chief Scientific Officer Compensation: $694.3kMr. Kory James Wentworth CPA (Age 45)CFO & Treasurer Dr. Jared Cohen J.D.Ph.D., General CounselMs. Kerry Robert M.S.Senior Vice President of PeopleMs. Karla MacDonaldChief Corporate Affairs OfficerMr. Kevin Healy Ph.D.Senior Vice President of Regulatory Affairs More Insider Trading Tools from MarketBeat Related Companies Phibro Animal Health Insider Trades WAVE Life Sciences Insider Trades Enliven Therapeutics Insider Trades Verve Therapeutics Insider Trades Intellia Therapeutics Insider Trades Collegium Pharmaceutical Insider Trades Akebia Therapeutics Insider Trades Spyre Therapeutics Insider Trades Mineralys Therapeutics Insider Trades Avadel Pharmaceuticals Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Do They Know Something? Insiders & Congress Buy UnitedHealthMicron Insiders Sell But Investors Should Buy, Buy, BuySizzling Insider Buys for Your High-Yield WatchlistInsider Selling at NVIDIA Could Turn Into an Opportunity The Top Insider Sells From Q2: Buy, Sell, or Hold? This page (NASDAQ:TRDA) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
